Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Preferred Stock

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on December 28, 2024.

Summary

• On December 28, 2024, Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into 37,760 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the company's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the transaction, Pershing directly owns 1,748,344 shares of Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (conversion of a note) by the CEO, which doesn't inherently signal positive or negative implications for the company's future performance.

Positives

• The conversion of the promissory note simplifies the company's capital structure.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The conversion could have a minor impact on shareholders due to the potential future dilution from the conversion of preferred stock to common stock.

Key Dates